DeepMed Research

GI-102

Generic Name: GI-102

Clinical Trials

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1

Recruiting

Conditions: Advanced Solid Tumor
Metastatic Solid Tumor
Soft Tissue Sarcoma (STS)
Platinum-resistant Ovarian Cancer (PROC)
Hepatocellular Carcinoma (HCC)
Colorectal Cancer (CRC)
HER2 Negative Breast Cancer
Cutaneous Melanoma
Renal Cell Carcinoma (RCC)

Interventions: Drug: GI-102 subcutaneous (SC)
Drug: GI-102
Drug: doxorubicin
Drug: paclitaxel
Drug: eribulin
Drug: trastuzumab deruxtecan (T-DXd)
Drug: pembrolizumab
Drug: bevacizumab

First Posted Date: 2023-04-24

Last Posted Date: 2024-11-25

Lead Sponsor: GI Innovation, Inc.

Target Recruit Count: 358

Registration Number: NCT05824975

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Minnesota, Rochester, Minnesota, United States

and more 7 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy